The patent pertains to certain drug screening methods that make use of the niacin receptor. Ligands of a role be played by the niacin receptor in regulating plasma lipid profiles, including HDL cholesterol, the so-called ‘good cholesterol.’ The invention set forth in the newly issued patent and Arena’s chemistry features represented the basis for initiating the cardiovascular disease collaboration with Merck. Related StoriesDiscovery could offer clues to how some infections control expression of genetic materialPresence of tophi in people with gout can increase risk of developing cardiovascular diseasePresence of connexin proteins suppresses principal tumor development’The invention set forth in this patent provides been instrumental in determining G Protein-Coupled Receptor targeted substances which have the potential to regulate plasma lipid profiles, including HDL cholesterol, similar to the therapeutic action of niacin,’ commented Jack Lief, Arena’s President and Chief Executive Officer.This new and efficient collision-avoidance software program based on the latest robotic trajectory-preparing algorithms makes experiment planning easier and more efficient than ever before. The PROTEUM2 suite is simple to use for instrument control, data collection, integration and scaling, structure remedy and model building. PROTEUM2 today features an automated pipeline for data acquisition and integration. Dr. In conjunction with the brand new automated data pipeline these systems are ideal for sample screening and offer extremely powerful platforms for home data collection.’..